AtonRa Partners’s Nurix Therapeutics NRIX Stock Holding History

AtonRa Partners’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$218K	Sell	21,102 -3,125	-13%	-$21.4K	0.43%	104
2023 Q3	$190K	Sell	24,227 -5,915	-20%	-$54K	0.4%	113
2023 Q2	$301K	Sell	30,142 -2,792	-8%	-$28.5K	0.47%	94
2023 Q1	$292K	Sell	32,934 -3,994	-11%	-$41.6K	0.43%	105
2022 Q4	$405K	Sell	36,928 -9,987	-21%	-$120K	0.52%	84
2022 Q3	$611K	Sell	46,915 -2,302	-5%	-$36.4K	0.6%	77
2022 Q2	$624K	Buy	49,217 +1,753	+4%	+$19.9K	0.57%	79
2022 Q1	$665K	Buy	47,464 +172	+0.4%	+$3.05K	0.36%	98
2021 Q4	$1.37M	Buy	47,292 +7,080	+18%	+$215K	0.48%	76
2021 Q3	$1.21M	Buy	40,212 +16,601	+70%	+$512K	0.4%	90
2021 Q2	$626K	Buy	+23,611	New	+$693K	0.23%	111

Other funds holding NRIX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

AtonRa Partners's NRIX Position: Q4 2023 in Review

AtonRa Partners reduced its Nurix Therapeutics (NRIX) stake by 13% in Q4 2023, selling an estimated $21.4K and leaving 21,102 shares worth $218K. The position accounts for 0.43% of the portfolio, ranked #104.

AtonRa Partners first reported a position in NRIX in Q2 2021 and has held it in 11 quarters since. The position peaked at $1.37M in Q4 2021. 130 funds tracked by Wall St. Rank hold NRIX as of Q4 2023.

AtonRa Partners held 21,102 shares of Nurix Therapeutics worth $218K as of Q4 2023.
AtonRa Partners sold 3,125 Nurix Therapeutics shares in Q4 2023, an estimated $21.4K.
Nurix Therapeutics made up 0.43% of AtonRa Partners's portfolio in Q4 2023, its #104 holding.
AtonRa Partners first reported a position in Nurix Therapeutics in Q2 2021 and has held it in 11 quarters since.
AtonRa Partners's Nurix Therapeutics position peaked at $1.37M in Q4 2021.
130 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q4 2023.

Based on AtonRa Partners's 13F filing for Q4 2023, filed 5 Feb 2024.